Ospedale Isola Tiberina Gemelli Isola
- Address
- Via Di Ponte Quattro Capi 39, 00186 Rome, Italy
Ospedale Isola Tiberina Gemelli Isola - Advanced Oncology and Specialized Disease Research Center
Ospedale Isola Tiberina Gemelli Isola is a leading medical research institution specializing in cutting-edge clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in oncology research, with comprehensive programs addressing gastrointestinal, breast, ovarian, and lung cancers, as well as pioneering work in neurodegenerative disorders including Alzheimer's disease and associated psychosis.
- Advanced oncology trials including colorectal cancer with biomarker-driven treatments, triple-negative breast cancer immunotherapy, ovarian cancer maintenance therapy, and non-small cell lung cancer combination therapies
- Neurodegenerative disease research focusing on Alzheimer's disease therapeutics and psychosis associated with dementia
- Gastroenterological disorders including eosinophilic gastritis, Clostridioides difficile infection prevention, and chronic kidney disease
- Specialized areas encompassing chronic spontaneous urticaria, neovascular age-related macular degeneration, type 2 diabetes complications, and prostate cancer radiotherapy
The center's research portfolio reflects a commitment to precision medicine and targeted therapies, with particular emphasis on liquid biopsy technology, circulating tumor DNA analysis, and personalized treatment strategies. The institution participates in multiple international collaborative trials, demonstrating expertise in both early-phase dose-finding studies and large-scale Phase III randomized controlled trials across diverse medical specialties.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Isola Tiberina Gemelli Isola
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease | AbbVie Deutschland GmbH & Co. KG | Phase II | Not Recruiting | — | Jun 2024 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Donanemab | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.